CalciMedica, Inc. Common Stock (CALC)vsBeiGene, Ltd. (ONC)
CALC
CalciMedica, Inc. Common Stock
$0.64
-3.70%
HEALTHCARE · Cap: $11.71M
ONC
BeiGene, Ltd.
$369.15
+1.83%
HEALTHCARE · Cap: $40.64B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
CALC
Avoid19
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CALC.
Margin of Safety
+80.3%
Fair Value
$1785.72
Current Price
$369.15
$1416.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
CALC has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.2x leaves little room for execution misses.
Key Dynamics to Monitor
CALC profiles as a value stock while ONC is a growth play — different risk/reward profiles.
CALC carries more volatility with a beta of 1.12 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 19/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies that target calcium-dependent pathways to address both acute and chronic health challenges. The company’s lead candidate, CM4620, aims to alleviate severe muscle cramps associated with sickle cell disease, underscoring its focus on meeting critical unmet medical needs. With a robust proprietary technology platform and an expanding pipeline of novel calcium modulators, CalciMedica is well-positioned for significant growth. Backed by an experienced management team and key strategic partnerships, the company presents a compelling investment opportunity within the biopharmaceutical sector.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?